Next Article in Journal
Clinical, Immunological, and Genetic Findings in a Cohort of Patients with the DiGeorge Phenotype without 22q11.2 Deletion
Next Article in Special Issue
Sentinel Lymph Node Biopsy in Malignant Melanoma of the Head and Neck: A Single Center Experience
Previous Article in Journal
The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support
Previous Article in Special Issue
Multispectral Imaging Algorithm Predicts Breslow Thickness of Melanoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 7
10.3390/jcm11072026
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years)

by
Robin Reschke
,
Konstantin Dumann
and
Mirjana Ziemer
*
Department of Dermatology, Allergology and Venereology, University Medical Center, 04103 Leipzig, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(7), 2026; https://doi.org/10.3390/jcm11072026
Submission received: 8 March 2022 / Revised: 29 March 2022 / Accepted: 2 April 2022 / Published: 5 April 2022
(This article belongs to the Special Issue Advance in Melanoma)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Most patients with high-risk melanomas develop metastasis within the first few years after diagnosis. However, late recurrence of melanoma is seen in patients that metastasize more than 10 years after the primary diagnosis; a metastasis after 15 years is considered an ultra-late recurrence. It is critical to better understand the clinical and biological characteristics of this subset of melanoma patients in order to offer an individual treatment plan and prevent metastasis. Methods: We retrospectively analyzed melanoma patients with recurrence ≥10 years after a primary diagnosis documented between 1993 and 2012 at the skin cancer center of the University Medical Center Leipzig, Germany. We conducted a comprehensive review of the literature and compared the results with our data. Available archived primary melanoma tissue was investigated with a seven-marker immunohistochemical signature (immunoprint®) previously validated to reliably identify high-risk patients within stages IB-III. Results: Out of 36 analyzed patients, a third metastasized ultra-late (≥15 years). The mean age at initial diagnosis was 51 years, with women being diagnosed comparatively younger than men. The largest proportion of patients with late recurrence had primary melanomas located on the trunk. The immunoprint® signature of the available primary melanomas allowed the accurate prediction of a high risk. However, it is difficult to draw a definitive conclusion from the small number of cases that could be analyzed with immunoprint® (n = 2) in this study. Apart from the primary tumor characteristics, the laboratory values at time of metastasis, comorbidities and outcome are also shown. Conclusion: Late and ultra-late recurrent melanomas seem not to differ from melanomas in general, apart from a distinctly higher proportion of lower leg localizations in ultra-late recurrent melanomas. The immunoprint® signature may help to identify high-risk primary tumors at the time of initial diagnosis. However, apart from the risk profile of the primary tumor, it seems that individual immune surveillance can control residual tumor cells for more than a decade. Advanced age and increasing comorbidities may contribute to a disturbed immunological balance.

1. Introduction

Melanoma incidence is continuously rising, and patients still die from metastatic disease, despite a portfolio of promising systemic treatment options [1,2]. Research still focuses on understanding the complex process of metastasis. A majority of patients with high-risk melanomas develop metastatic disease within the first three years after the diagnosis (65–85%), mostly in the first two years (55–67%) [3]. Breslow’s depth and the ulceration of the primary melanoma are the established histomorphologic parameters used for prognosis predictions. However, there is still a strong need for biomarkers that facilitate, at the time of primary diagnosis, a more precise identification of patients with a higher risk for recurrence [3,4,5]. Late recurrence of melanoma with metastasis ten years after the initial diagnosis illustrates that decades may pass between the detachment of individual tumor cells from the primary melanoma, their migration through blood and lymphatic vessels and the clinical manifestation of distant metastases. Unquestionably, in addition to histomorphologic characteristics, there seem to exist further factors influencing disease spread. It is a complex interplay of various factors that enables so-called “tumor dormancy”. The patient’s immune system plays an important role in regulating tumor growth with the secretion of interferon-γ and interleukin−2, among other substances [6,7]. Particular cellular mechanisms can also contribute to this phenomenon. Tumor cells can exclude themselves from the cell cycle and survive in a dormant state with distinctly reduced metabolic activity [6,7]. Another regulating mechanism is the angiogenic activity of tumor cells. In a stable state of cell division and death, the activation and inhibition of angiogenic factors are balanced. When this stable state shifts towards angiogenesis, tumor cells will grow (angiogenic switch) [7]. It is not only the cell’s intrinsic or immune-mediated mechanisms that influence the tumor cell’s survival but also environmental factors. Oxidative stress is a limiting factor for metastatic spread because it leads to the cell death of detached tumor cells. These rely on antioxidants such as glutathione or nicotinamide adenine dinucleotide phosphate (NADPH). Cells die without sufficient levels of these molecules [6,8]. Li et al. have shown that, among lung cancer patients, smokers show a better response to programmed cell death protein (PD)1/PD1-ligand 1-inhibitors than non-smokers [9]. One potential explanation could be the increased oxidative stress in patients who smoke [10]. A particular subpopulation of melanoma cells called cancer stem cells (CSC) or melanoma stem cells (MSC) is established during cellular stress [11]. These CD20+MSC can lead to tumor maintenance and migration. The group of melanoma patients with so-called late or ultra-late metastasis may help elucidate this concept of “tumor dormancy”.

2. Material and Methods

Included in the study were patients with late recurrent melanoma metastasizing ten or more years after the initial diagnosis of their primary tumors, as documented by the skin cancer center of the Department of Dermatology at the University Medical Center Leipzig, Germany, between 1993 and 2012. Initially, 38 patients fulfilled the inclusion criteria and were included in the study. Two patients developed a second primary melanoma before the onset of the metastatic disease and were excluded. Ultimately, 36 cases were analyzed. Twelve of the 36 patients (33.3%) metastasized more than 15 years after the primary melanoma, thus qualifying for so-called ultra-late recurrence. Collected clinical characteristics included the characteristics of the primary melanoma such as localization, the presence of ulceration and Breslow’s depth; the age at primary diagnosis and at the onset of metastatic disease; comorbidities; and outcome (Supplementary Figure S1).
Laboratory results from S100ß protein and lactate dehydrogenase (LDH) as well as a differential blood count and thrombocytes were collected at the time of metastasis. Laboratory results from the time of primary diagnosis were not available. Clinical parameters were compared with 17 cohorts of late recurrent melanomas published in the literature between 1983 and 2021. Case reports were excluded. We additionally aimed to examine the available primary melanomas immunohistochemically with a 7-marker immunohistochemical signature, consisting of Bax, Bcl-X, PTEN, COX-2, (loss of) ß-Catenin, (loss of) MTAP and (presence of) CD20 (immunoprint®) [12]. Apart from three cases, however, the tumor blocks of the primaries more than 10 years after diagnosis did not exist. The main reason is the limit on archiving based on German archival storage guidelines. Of those cases, formalin-fixed and paraffin-embedded tissue sections were stained with the immunoprint® signature. The determination and scoring of the signature were previously described in detail and validated in larger patient cohorts [12,13]. This analysis was conducted in cooperation with Synvie GmbH, Munich, Germany. The stained slides were evaluated by an independent external dermatologist and histopathologist (MD) and one experienced Synvie lab scientist (PhD) in a blinded manner.

3. Results

Our study cohort included equal gender representation: 18 male and 18 female patients. The mean age at the time of initial diagnosis was 51 years (30–76 years) (Table 1).
In more than half of the patients (n = 19, 52.8%), the primary melanoma was found on the trunk; in seven patients, it was on a lower extremity (19.4%); in five patients, it was on an upper extremity (13.9%); in another five patients, it was in the head and neck region (13.9%). Concerning the gender distribution, the primary melanoma in both male and female patients was predominantly localized at the trunk. However, in women, primaries on the lower and upper extremities, taken together, also comprised 44.4%. The period between the primary melanoma and metastasis was, on average, 15 years (10–33 years) (Table 1). The mean age of patients at the time of metastasis was 66 years. There was no significant difference between the organ manifestation of metastatic spread and the time intervals. Detailed information on the primary tumor was documented in 24 of 36 patients (66.7%). Half of these patients were male, and half were female. The average Breslow’s depth was 1.8 mm (0.4–4.5 mm, from pT1a to pT2b) (Table 2). In a third of patients (n = 12), documentation of detailed histopathological information for the primary melanoma was not available in the department’s database or that of the pre-treating physicians (n = 12) because of the long periods between primary melanoma and metastases.
Almost 17% of melanomas showed an ulceration (Table 2). There was no association between tumor thickness and time until metastasis. Tumor markers S100 and LDH were documented in two-thirds of the patients (66.7%) at the time of metastatic disease. The median S100 level was 0.07 ng/mL (0.05–2.6 ng/mL, mean 0.28 ng/mL, normal: <0.105 ng/mL) (Table 3).
In 42% of the male patients, the S100 value was increased, whereas the majority of women (60%) had an increased S100 value. The median value of LDH at the time of metastasis was 4.7 µkat/L (2.9–10.2 µkat, normal: <3.75 µkat/L) (Table 4). Increased LDH values at the time of metastatic disease were seen in the majority of patients independently of gender but more frequently in women (66.7% of men and 83.3% of women) (Table 4).
For 18 of 36 analyzed patients (50% women, 50% men) we had results of a differential blood count at the time of metastasis. The majority of patients had normal differential blood counts (Supplementary Table S1). Four patients showed leukocytosis and four patients lymphopenia (22.2%). Six patients presented with neutrophilia and one patient with eosinophilia. The neutrophil-to-lymphocyte ratio (NLR) was higher than 5 (normal: 0.78–3.53) in three women and three men (33.3% of all patients) [14]. Table 5 shows an association between a higher NLR and a longer period until the onset of metastatic disease.
In 20 of 36 patients (55.6%), information about comorbidities at the time of the initial diagnosis of the primary melanoma could be obtained. At the time of metastasis, this information was available from 33 of 36 patients (91.7%). The most frequently documented comorbidity was hypertension. At the time of initial diagnosis, hypertension was documented in eight patients (40%), compared to 23 patients at the time of metastatic disease (69.7%). Seven patients (21.2%) had a thromboembolic event (deep leg vein thrombosis, pulmonary artery embolism, myocardial infarction or ischemic apoplex) at the time of metastasis. At the time of primary diagnosis, only one patient had a documented ischemic apoplex. A non-cutaneous secondary tumor was diagnosed in four patients (16.7%) between the primary melanoma and the onset of metastatic disease (bladder cancer, lung cancer, intraductal papillary mucinous tumor of the pancreas and myeloproliferative neoplasm). At the time of the primary diagnosis, one patient had a renal cell carcinoma.
In Supplementary Table S2, the cases with ultra-late recurrence (metastases after more than 15 years) were compared to the cases with occurrences of metastases after 10–15 years. In total, 12 of 36 patients metastasized after more than 15 years (33.3%). Eight of these 12 patients were men. The age of patients at the time of initial diagnosis did not differ between patients with late and ultra-late recurrence of melanoma. Breslow’s depth and tumor markers (S100 and LDH) were also comparable between groups. The main location of the primary melanoma was different in late and ultra-late cases. In ultra-late recurrent patients, the majority of primary melanomas was on the lower extremities. Only a fourth of melanomas was located at the trunk. By contrast, in cases with late recurrence of melanoma, two-thirds of melanomas were found at the trunk and only five at the extremities.
Archival tissue from the primary tumor was limited to three cases. One of those was not evaluable due to immense melanin pigmentation (Supplementary Figure S1). Of the two remaining, patient A was a female patient who had an ulcerated nodular melanoma with a Breslow’s depth of 2.6 mm located at the trunk. The period between the primary diagnosis and the onset of metastatic disease was eleven years. Subsequent staining with a previously validated immunohistochemical signature profile was able to stratify the patient with a high-risk score of 0.169 (<0.135 = low-risk; >0.135 = high-risk) and thereby correctly “predicted” the recurrence (Figure 1) [12,13]. Patient B was a female patient who had a superficial spreading melanoma with a Breslow’s depth of 0.9 mm located at the trunk. The period between the primary diagnosis and the onset of metastatic disease was ten years. Staining with the immunoprint® profile was able to stratify the patient with a high-risk score of 0.200 and correctly “predicted” the recurrence as well (Figure 2).

4. Discussion

In summary, 36 patients with late recurrence of melanoma were analyzed. The mean age at diagnosis of the primary melanoma was 51 years. The mean time until the onset of metastatic disease was 15 years. At the time of the initial diagnosis, women were generally younger than men, which is consistent with the data of all melanoma cases documented in the German Cancer Registry [15]. Taking into account that the likelihood of late recurrence decreases in elderly patients, the age distribution of our cohort showed that patients older than 70 years were less represented. Comorbidities and natural death potentially anticipate possible late recurrences of melanoma. The gender distribution was equal among age groups. Men had more primary tumors at the trunk, whereas in women, they were mostly localized at the trunk but also on the extremities to nearly the same extent. This finding is consistent with the pattern of melanoma distribution described in the literature [16]. The mean Breslow’s depth of primary melanomas was 1.8 mm. In advanced disease stages, eosinophilia in peripheral blood is considered to be a good prognostic factor. It has been correlated with significantly better survival in melanoma patients [17]. On the other hand, a neutrophil-to-lymphocyte ratio (NLR) > 5 is considered a negative prognostic factor [18]. Patients in our study collective with a higher NLR showed a longer recurrence-free survival time (Table 5) but a worse outcome (9% vs. 17% overall survival). Additionally, LDH was increased in the majority of patients at metastasis. S100, however, was only increased in half of the patients (Table 3 and Table 4). This could argue for a higher sensitivity of LDH as opposed to S100 as a marker for disease progression. Nevertheless, in the literature, S100 is described as more sensitive towards newly occurring metastases [19]. Interestingly, in our patients, S100 and LDH at the time of metastatic disease were higher in women than in men. A limiting factor of this analysis is the relatively small samples size. A gender-specific predisposition has not been shown in the literature studies (Table 6).
The median age at the time of primary diagnosis was 51 years. The mean age of all late recurrence patients recorded in the literature and summarized in Table 6 was 45 years. The mean of the period between the primary diagnosis and the onset of metastatic disease is 15 years in our study; this is only half a year longer than in the corresponding literature. Mean Breslow’s depth is also comparable to the cited literature. Ultra-late recurrent melanomas were more frequently found in the lower extremity (41.7%), a more favorable localization in terms of prognosis [34,35]. Indeed, the EORTC nomogram—a valuable predictive score—includes anatomical location in addition to Breslow’s thickness and ulceration status [36]. The more favorable prognosis of limb melanomas might be explained by an ameliorated immune surveillance of melanoma cells in this location. Tsao et al. only focused on ultra-late recurrent melanomas (>15 years) in their study [27]. The lower mean age of their patients at primary diagnosis (36 years) is remarkable (Table 6). Ultra-late metastasizing patients in our own dataset had a mean age of 50 years at primary diagnosis, comparable to that of patients with late metastasis. A correlation between ultra-late recurrence of melanoma and age at primary diagnosis was not seen. Archived tissue from the primary melanoma was eligible for testing with the immunohistochemical signature (immunoprint®) for two patients; it showed a high-risk score and therefore correctly predicted a late recurrence (risk score 0.160, Figure 1). This underlines the potential of predictive signatures used on formalin-fixed paraffin-embedded tissue to filter out these high-risk tumors. It is also consistent with previously reported results from our group showing a very high sensitivity of relapse prediction (>94%) in sentinel-negative patients (stages IB–IIC) with this signature [12]. The immunoprint signature also incorporates CD20 positivity and thereby potentially reflects the pro-metastatic effect of CD20+MSC. Due to the retrospective nature of the study of protracted cases with late or ultra-late recurrent melanomas, the treatment regimens have changed over time. At the time of the primary diagnosis, many patients with higher risk melanomas (≥tumor stage pT1b) might have profited from sentinel lymph node removal and adjuvant therapies. It can be speculated that a fraction of our patients would have been detected early, and late recurrence of melanoma might have been prevented. Moreover, in the future, gene or immunohistochemical signatures can help characterize the tumor microenvironment and identify patients with potential late recurrent melanoma early on. Risk scores from gene or immunohistochemical signatures have the potential to tailor adjuvant therapy independent of the histopathological criteria of the primary melanoma or the sentinel lymph node results. Acceptance rate of adjuvant therapies is high in stage III melanoma patients [37]. Additionally, further follow-up examinations after three years with lymph node sonography and computer tomography should be discussed in patients classified with high-risk scores. Finally, studies with a larger sample size and with control groups are still needed to better understand “tumor dormancy” and the potential co-factors for recurrence in melanoma.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11072026/s1, Figure S1: Immunohistochemical staining pigmented melanoma. Table S1: Differential blood count of entire study collective, divided into normal, increased or decreased. Table S2: Comparison ultra-late recurrence of melanoma (>15 years between primary melanoma and metastasis) and late recur-rence melanoma (10–15 years between primary melanoma and metastasis).

Author Contributions

M.Z conceptualization, K.D. and M.Z. data curation, R.R., K.D. and M.Z. data acquisition and interpretation, R.R., K.D. and M.Z., writing and original draft preparation, R.R. and M.Z. review of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

We acknowledge financial support from Leipzig University Library for Open Access Publishing. Immunohistochemical staining (immunoprint®) was supported by Synvie GmbH, Munich, Germany.

Institutional Review Board Statement

This study was approved by the University Ethics Committee Leipzig, Germany (004/22-ek).

Informed Consent Statement

Patient consent was waived due to the retrospective study design.

Data Availability Statement

The data presented in this study are available within the article.

Acknowledgments

We thank Silke Seibold, Synvie GmbH and Annette Gomolka, for blindly evaluating the staining results. Synvie had no part in the design of the study. We thank the information specialists Kristin Rothe and Felix Schmidt from the University Cancer Center Leipzig for data extraction from the tumor register files.

Conflicts of Interest

Mirjana Ziemer received lecture fees from Bristol-Myers Squibb, Roche Pharma AG, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Sanofi-Aventis Deutschland GmbH and Novartis Pharma GmbH, received financial support for congress participation from Bristol-Myers Squibb, Novartis Pharma and Amgen GmbH and served as a member of expert panels on cutaneous adverse reactions for Pfizer INC.

References

  1. Garbe, C.; Leiter, U. Melanoma epidemiology and trends. Clin. Dermatol. 2009, 27, 3–9. [Google Scholar] [CrossRef] [PubMed]
  2. Herbert, A.; Koo, M.M.; Barclay, M.E.; Greenberg, D.C.; Abel, G.A.; Levell, N.J.; Lyratzopoulos, G. Stage-specific incidence trends of melanoma in an English region, 1996–2015, Longitudinal analyses of population-based data. Melanoma Res. 2018, 30, 279–285. [Google Scholar] [CrossRef] [PubMed]
  3. Bredgaard, R.; Lock-Andersen, J. Recurrence of cutaneous malignant melanoma after more than 20 years. J. Plast. Surg. Hand Surg. 2011, 45, 113–116. [Google Scholar] [CrossRef] [PubMed]
  4. Faries, M.B.; Steen, S.; Ye, X.; Sim, M.; Morton, D.L. Late recurrence in melanoma: Clinical implications of lost dormancy. J. Am. Coll. Surg. 2013, 217, 27–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Callaway, M.P.; Briggs, J.C. The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br. J. Plast. Surg. 1989, 42, 46–49. [Google Scholar] [CrossRef]
  6. Sosa, M.S.; Bragado, P.; Aguirre-Ghiso, J.A. Mechanisms of disseminated cancer cell dormancy: An awakening field. Nat. Rev. Cancer 2014, 14, 611–622. [Google Scholar] [CrossRef]
  7. Senft, D.; Ronai, Z.A. Immunogenic, cellular, and angiogenic drivers of tumor dormancy—A melanoma view. Pigment. Cell Melanoma Res. 2016, 29, 27–42. [Google Scholar] [CrossRef] [Green Version]
  8. Piskounova, E.; Agathocleous, M.; Murphy, M.M.; Hu, Z.; Huddlestun, S.E.; Zhao, Z.; Leitch, A.M.; Johnson, T.M.; DeBerardinis, R.J.; Morrison, S.J. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 2015, 527, 186–191. [Google Scholar] [CrossRef] [Green Version]
  9. Li, B.; Huang, X.; Fu, L. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: A meta-analysis. OncoTargets Ther. 2018, 11, 3691–3696. [Google Scholar] [CrossRef] [Green Version]
  10. Charalabopoulos, K.; Assimakopoulos, D.; Karkabounas, S.; Danielidis, V.; Kiortsis, D.; Evangelou, A. Effects of cigarette smoking on the antioxidant defence in young healthy male volunteers. Int. J. Clin. Pract. 2005, 59, 25–30. [Google Scholar] [CrossRef]
  11. Nguyen, N.; Couts, K.L.; Luo, Y.; Fujita, M. Understanding melanoma stem cells. Melanoma Manag. 2015, 2, 179–188. [Google Scholar] [CrossRef] [PubMed]
  12. Reschke, R.; Gussek, P.; Ziemer, M. Identifying High-Risk Tumors within AJCC Stage IB-III Melanomas Using a Seven-Marker Immunohistochemical Signature. Cancers 2021, 13, 2902. [Google Scholar] [CrossRef] [PubMed]
  13. Meyer, S.; Fuchs, T.J.; Bosserhoff, A.K.; Hofstädter, F.; Pauer, A.; Roth, V.; Buhmann, J.M.; Moll, I.; Anagnostou, N.; Brandner, J.M.; et al. A seven-marker signature and clinical outcome in malignant melanoma: A large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE 2012, 7, e38222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Forget, P.; Khalifa, C.; Defour, J.P.; Latinne, D.; Van Pel, M.C.; De Kock, M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res. Notes 2017, 10, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Gesellschaft der Epidemiologischen Krebsregister Deutschland. Melanom Atlas. Available online: http://atlas.gekid.de/CurrentVersion/atlas.html (accessed on 15 March 2022).
  16. Stanienda-Sokół, K.; Salwowska, N.; Sławińska, M.; Wicherska-Pawłowska, K.; Lorenc, A.; Wcisło-Dziadecka, D.; Wydmański, J.; Majewski, W. Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and Age. Asian Pac. J. Cancer Prev. APJCP 2017, 18, 3081–3086. [Google Scholar] [CrossRef]
  17. Tahery, D.P.; Moy, R.L. Lack of predictive factors in late recurrence of stage I melanoma. Int. J. Dermatol. 1992, 31, 629–631. [Google Scholar] [CrossRef]
  18. Ding, Y.; Zhang, S.; Qiao, J. Prognostic value of neutrophil-to-lymphocyte ratio in melanoma: Evidence from a PRISMA-compliant meta-analysis. Medicine 2018, 97, e11446. [Google Scholar] [CrossRef]
  19. Krähn, G.; Kaskel, P.; Sander, S.; Waizenhöfer, P.J.; Wortmann, S.; Leiter, U.; Peter, R.U. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001, 21, 1311–1316. [Google Scholar]
  20. Sarac, E.; Wilhelmi, J.; Thomas, I.; Leiter, U.; Keim, U.; Eigentler, T.K.; Garbe, C.; Amaral, T. Late recurrence of melanoma after 10 years—Is the course of the disease different from early recurrences? J. Eur. Acad. Dermatol. Venereol. 2020, 34, 977–983. [Google Scholar] [CrossRef]
  21. Osella-Abate, S.; Ribero, S.; Sanlorenzo, M.; Maule, M.M.; Richiardi, L.; Merletti, F.; Tomasini, C.; Marra, E.; Macripò, G.; Fierro, M.T.; et al. Risk factors related to late metastases in 1372 melanoma patients disease free more than 10 years. Int. J. Cancer 2015, 136, 2453–2457. [Google Scholar] [CrossRef]
  22. Hohnheiser, A.M.; Gefeller, O.; Göhl, J.; Schuler, G.; Hohenberger, W.; Merkel, S. Malignant melanoma of the skin: Long-term follow-up and time to first recurrence. World J. Surg. 2011, 35, 580–589. [Google Scholar] [CrossRef] [PubMed]
  23. Hansel, G.; Schönlebe, J.; Haroske, G.; Wollina, U. Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J. Eur. Acad. Dermatol. Venereol. 2010, 24, 833–836. [Google Scholar] [CrossRef] [PubMed]
  24. Leman, J.A.; Mac Kie, R.M. Late (10 years) recurrence of melanoma: The Scottish experience. Br. J. Dermatol. 2003, 148, 372–373. [Google Scholar] [CrossRef] [PubMed]
  25. Schmid-Wendtner, M.H.; Baumert, J.; Schmidt, M.; Konz, B.; Hölzel, D.; Plewig, G.; Volkenandt, M. Late metastases of cutaneous melanoma: An analysis of 31 patients. J. Am. Acad. Dermatol. 2000, 43, 605–609. [Google Scholar] [CrossRef]
  26. Peters, A.; Lippold, A.; Hundeiker, M. Melanomerstmetastasen nach 10 und mehr Jahren Erscheinungsfreiheit. Hautarzt 1997, 48, 311–317. [Google Scholar] [CrossRef] [PubMed]
  27. Tsao, H.; Cosimi, A.B.; Sober, A.J. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997, 79, 2361–2370. [Google Scholar] [CrossRef]
  28. Crowley, N.J.; Seigler, H.F. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann. Surg. 1990, 212, 173–177. [Google Scholar] [CrossRef]
  29. McEwan, L.; Smith, J.G.; Matthews, J.P. Late recurrence of localized cutaneous melanoma: Its influence on follow-up policy. Plast. Reconstr. Surg. 1990, 86, 527–534. [Google Scholar] [CrossRef]
  30. Landthaler, M.; Braun-Falco, O.; Schlamminger, F.; Schubert-Fritschle, G. Späte Metastasierung bei malignem Melanom der Haut. Dtsch. Med. Wochenschr. 1989, 114, 1149–1152. [Google Scholar] [CrossRef]
  31. Gutman, M.; Klausner, J.M.; Inbar, M.; Rozin, R.R. Late recurrence of stage I malignant melanoma. J. Surg. Oncol. 1989, 42, 96–98. [Google Scholar] [CrossRef]
  32. Shaw, H.M.; Beattie, C.W.; McCarthy, W.H.; Milton, G.W. Late relapse from cutaneous stage I malignant melanoma. Arch. Surg. 1985, 120, 1155–1159. [Google Scholar] [CrossRef] [PubMed]
  33. Briele, H.A.; Beattie, C.W.; Ronan, S.G.; Chaudhuri, P.K.; Das Gupta, T.K. Late recurrence of cutaneous melanoma. Arch. Surg. 1983, 118, 800–803. [Google Scholar] [CrossRef] [PubMed]
  34. Rogers, G.S.; Kopf, A.W.; Rigel, D.S.; Friedman, R.J.; Levine, J.L.; Levenstein, M.; Bart, R.S.; Mintzis, M.M. Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch. Dermatol. 1983, 119, 644–649. [Google Scholar] [CrossRef] [PubMed]
  35. Tas, F.; Erturk, K. Limb melanomas: Acral melanomas have worse survival. J. Dermatol. Treat. 2021, 1–8. [Google Scholar] [CrossRef]
  36. El Sharouni, M.A.; Ahmed, T.; Witkamp, A.J.; Sigurdsson, V.; van Gils, C.H.; Nieweg, O.E.; Scolyer, R.A.; Thompson, J.F.; van Diest, P.J.; Lo, S.N. Predicting recurrence in patients with sentinel node-negative melanoma: Validation of the EORTC nomogram using population-based data. Br. J. Surg. 2021, 108, 550–553. [Google Scholar] [CrossRef]
  37. Reschke, R.; Jäger, I.; Mehnert-Theuerkauf, A.; Ziemer, M. Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies. J. Dtsch. Dermatol. Ges. 2021, 19, 215–221. [Google Scholar] [CrossRef]
Jcm 11 02026 g001 550
Figure 1. Immunohistochemical staining and risk score stratification Patient A. 1+: weak cytoplasmic staining or less than 20% of cell nuclei stained; 2+: moderate cytoplasmic staining or 21 to 50% of cell nuclei stained. COX-2 = Cyclooxygenase-2, PTEN = Phosphatase and Tensin Homolog, Bax = Bcl-2-associated X protein, MTAP = S-methyl-5′-thioadenosine phosphorylase.
Figure 1. Immunohistochemical staining and risk score stratification Patient A. 1+: weak cytoplasmic staining or less than 20% of cell nuclei stained; 2+: moderate cytoplasmic staining or 21 to 50% of cell nuclei stained. COX-2 = Cyclooxygenase-2, PTEN = Phosphatase and Tensin Homolog, Bax = Bcl-2-associated X protein, MTAP = S-methyl-5′-thioadenosine phosphorylase.
Jcm 11 02026 g001
Jcm 11 02026 g002 550
Figure 2. Immunohistochemical staining and risk score stratification Patient B. 0% of cell nuclei stained; 1+: weak cytoplasmic staining or less than 20% of cell nuclei stained; 2+: moderate cytoplasmic staining or 21 to 50% of cell nuclei stained. COX-2 = Cyclooxygenase-2, PTEN = Phosphatase and Tensin Homolog, Bax = Bcl-2-associated X protein, MTAP = S-methyl-5′-thioadenosine phosphorylase.
Figure 2. Immunohistochemical staining and risk score stratification Patient B. 0% of cell nuclei stained; 1+: weak cytoplasmic staining or less than 20% of cell nuclei stained; 2+: moderate cytoplasmic staining or 21 to 50% of cell nuclei stained. COX-2 = Cyclooxygenase-2, PTEN = Phosphatase and Tensin Homolog, Bax = Bcl-2-associated X protein, MTAP = S-methyl-5′-thioadenosine phosphorylase.
Jcm 11 02026 g002
Table
Table 1. Characteristics of study collective, gender comparison.
Table 1. Characteristics of study collective, gender comparison.
OverviewTotalMaleFemale
n (%)36 (100%)18 (50%)18 (50%)
MeanMedianMaximumMinimumMeanMedianMaximumMinimumMeanMedianMaximumMinimum
Age at primary diagnosis [years]51.450.67627.850.951.975.827.851.850.67630.2
Age at manifestation of metastatic disease [years]66.368.289.44166.769.389.44165.866.487.741.2
Years until occurrence of metastases 14.912.433.210.115.813.333.210.11411.929.710.1
Localization of primary melanoma:
Head/Neck n (%)5 (13.9%)3 (16.7%)2 (11.1%)
Trunk n (%)19 (52.8%)11 (61.1%)8 (44.4%)
Upper extremity n (%)5 (13.9%)1 (5.6%)4 (22.2%)
Lower extremity n (%)7 (19.4%)3 (16.7%) 4 (22.2%)
Table
Table 2. Histopathological parameter of the primary melanoma, gender comparison.
Table 2. Histopathological parameter of the primary melanoma, gender comparison.
Primary Melanoma HistopathologyTotalMaleFemale
n (%)24 (100%)12 (50%)12 (50%)
Ulceration, n (%)4 (16.7%)2 (16.7%)2 (16.7%)
MeanMedianMaximumMinimumMeanMedianMaximumMinimumMeanMedianMaximumMinimum
Breslow’s depth [mm]1.81.54.50.41.71.630.41.81.44.50.6
Table
Table 3. Tumor marker S100, gender comparison. Normal S100 vs. increased values. One extraordinary outlier with S100 9.39 ng/mL was excluded from the calculation as it biases the overall picture in this smaller cohort.
Table 3. Tumor marker S100, gender comparison. Normal S100 vs. increased values. One extraordinary outlier with S100 9.39 ng/mL was excluded from the calculation as it biases the overall picture in this smaller cohort.
S100 at the Time of Metastatic DiseaseTotalMaleFemale
n (%)24 (100%)14 (58.3%)10 (41.7%)
S100 normal n (%) (<0.105 ng/mL)14 (58.3%)10 (71.4%)4 (40%)
S100 increased n (%) (≥0.105 ng/mL)10 (41.7%)4 (28.6%)6 (60%)
MeanMedianMaximumMinimumMeanMedianMaximumMinimumMeanMedianMaximumMinimum
S100 (without one outlier) [ng/mL]0.280.072.160.050.250.072.160.050.330.111.850.05
Table
Table 4. Tumor marker LDH in the entire study collective, gender comparison. Normal LDH vs. increased values. One extraordinary outlier with LDH 21.3µkat/L was excluded from the calculation as it biases the overall picture in this smaller cohort.
Table 4. Tumor marker LDH in the entire study collective, gender comparison. Normal LDH vs. increased values. One extraordinary outlier with LDH 21.3µkat/L was excluded from the calculation as it biases the overall picture in this smaller cohort.
LDH at the Time of Metastatic DiseaseTotalMaleFemale
n (%)24 (100%)12 (50%)12 (50%)
LDH normal n (%) (2.25–3.55 µkat/L)6 (25%)4 (33.3%)2 (16.7%)
LDH increased n (%) (>3.55 µkat/L)18 (75%)8 (66.7%)10 (83.3%)
MeanMedianMaximumMinimumMeanMedianMaximumMinimumMeanMedianMaximumMinimum
LDH (without one outlier [ng/mL]5.14.710.22.94.84.78.72.95.44.710.23.2
Table
Table 5. Time period until metastatic disease correlated with neutrophil-lymphocyte-ratio (NLR) at the time of metastasis.
Table 5. Time period until metastatic disease correlated with neutrophil-lymphocyte-ratio (NLR) at the time of metastasis.
Neutrophil-to-Lymphocyte-Ratio (NLR)≤5>5
Time period until metastatic disease [years]Mean13.9719.31
Median12.3615.36
Table
Table 6. Comparison of our study collective with cohorts of late recurrence melanoma from 17 publications. * Tsao et al. (1997) investigated only ultra-late recurrence of melanoma (metastatic disease > 15 years after primary diagnosis) ** Percentage refers to the cases with histopathological record (n = 24). LR = late recurrence.
Table 6. Comparison of our study collective with cohorts of late recurrence melanoma from 17 publications. * Tsao et al. (1997) investigated only ultra-late recurrence of melanoma (metastatic disease > 15 years after primary diagnosis) ** Percentage refers to the cases with histopathological record (n = 24). LR = late recurrence.
n (Total Cases)% LR
Melanoma		n (LR
Melanoma >10 Years)		n (Female)n (Male)Age at
Primary
Diagnosis (Years) 		Period Until Metastasis (Years)Breslow’s Depth
(mm)		UlcerationLocalization: TrunkLocalization: Lower
Extremity		Localization: Upper
Extremity		Localization: Head/Neck
Reschke (2022)--3618 (50%)18 (50%)5114.91.84 (16.7%) **19 (52.8%)6 (16.7%)6 (16.7%)5 (13.9%)
Sarac [20] (2020)1537 9945 (45.5%)54 (54.5%)-14.5-8 (13.6%)44 (44.4%)29 (29.3%)17 (17.2%)9 (9.1%)
Osella-Abate [21] (2015)35802.2%7746 (59.7%)31 (40.3%)48-2.37 (9.1%)40 (51.9%)31 (40.3%)06 (7.8%)
Faries [4] (2013)--406171 (41.9%)235 (57.6%)4115.71.222 (5.4%)185 (45.3%)155 (38.0%)68 (16.7%)
Hohnheiser [22] (2011)20621.6%34--52-------
Hansel [23] (2010)23140.9%2013 (65%)7 (35%)4413.924 (20%)6 (30.0%)9 (45.0%)4 (20.0%)1 (5.0%)
Leman [24] (2003)--2513 (52%)12 (48%)-11------
Schmid-Wendtner [25] (2000)62980.5%3115 (4.4%)16 (51.6%)-12.61.4-16 (51.6%)---
Peters [26] (1997)--3620 (55.6%)16 (44.4%)5012.51.8-12 (33.3%)11 (30.6%)5 (13.9%)8 (22.2%)
Tsao [27] (1997) *27660.7%2010 (50%)10 (50%)3618.7--7 (35.0%)10 (50.0%)3 (15.0%)
Tahery [17] (1992)43010.2%83 (37.5%)5 (62.5%)4315.3-1 (12.5%)2 (25.0%)4 (50.0%)2 (25.0%)0
Crowley [28] (1990)71042.4%16889 (53.0%)79 (47.0%)-14.31.6-67 (39.9%)67 (39.9%)21 (12.5%)
McEwan [29] (1990)7691.4%117 (63.6%)4 (36.4%)4514.21.32 (18.2%)3 (27.3%)3 (27.3%)3 (27.3%)2 (18.1%)
Landthaler [30] (1989)24030.4%107 (70%)3 (30%)--1.7-4 (40.0%)2 (20.0%)2 (20.0%)2 (20.0%)
Gutman [31] (1989)5101.1%62 (33.3%)4 (66.7%)46---2 (33.3%)3 (50.0%)1 (16.7%)0
Callaway [5] (1989)--55 (100%)0 (0%)5112.91.8004 (80.0%)1 (20.0%)
Shaw [32] (1985)--3416 (47.1%)18 (52.9%)-13.72-11 (32.4%)18 (52.9%)5 (14.7%)
Briele [33] (1983)--76 (85.7%)1 (14.3%)2716.6--1 (14.3%)5 (71.4%)1 (14.3%)0
Total 934441 (49%)459 (51%) 375 (42.9%)352 (41.7%)122 (14.5%)
Average 1.1% 4514.31.7
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Reschke, R.; Dumann, K.; Ziemer, M. Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years). J. Clin. Med. 2022, 11, 2026. https://doi.org/10.3390/jcm11072026

AMA Style

Reschke R, Dumann K, Ziemer M. Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years). Journal of Clinical Medicine. 2022; 11(7):2026. https://doi.org/10.3390/jcm11072026

Chicago/Turabian Style

Reschke, Robin, Konstantin Dumann, and Mirjana Ziemer. 2022. "Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years)" Journal of Clinical Medicine 11, no. 7: 2026. https://doi.org/10.3390/jcm11072026

APA Style

Reschke, R., Dumann, K., & Ziemer, M. (2022). Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years). Journal of Clinical Medicine, 11(7), 2026. https://doi.org/10.3390/jcm11072026

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop